Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems), By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis), By Region and Competition, 2020-2030F

Market Overview

Global Circulating Tumor Cells Market was valued at USD 6.96 Billion in 2024 and is expected to reach USD 10.63 Billion by 2030 with a CAGR of 7.52% during the forecast period. The global circulating tumor cells (CTCs) market is witnessing significant growth, driven by the increasing demand for early cancer detection, personalized medicine, and advancements in liquid biopsy technologies. Circulating tumor cells are cancer cells that have detached from the primary tumor and entered the bloodstream, making them an important biomarker for understanding cancer progression and metastasis. The ability to detect and analyze CTCs has transformed cancer diagnostics and treatment monitoring, positioning the market for robust expansion in the coming years.

One of the key drivers of the global CTCs market is the growing demand for non-invasive diagnostic methods. Traditional cancer diagnostic techniques, such as biopsies, are invasive and often cause discomfort to patients. Liquid biopsy, which involves detecting CTCs in a simple blood sample, offers a less invasive alternative while providing valuable insights into the molecular characteristics of tumors. As patients and healthcare providers increasingly prioritize early detection and less invasive procedures, the CTCs market is poised to grow.

Despite its growth potential, the global circulating tumor cells market faces certain challenges. One of the primary obstacles is the technical difficulty of isolating and analyzing CTCs due to their low concentration in the bloodstream. Developing cost-effective and efficient methods for CTC detection remains a key challenge for the industry. Additionally, regulatory hurdles and the high cost of advanced detection technologies may slow market expansion in some regions.

Key Market Drivers

Growth in Healthcare Industry

The global circulating tumor cells (CTCs) market is experiencing notable growth, driven primarily by the rapid expansion of the healthcare industry. The WHO has introduced the "Guide to Cancer Early Diagnosis," designed to assist policymakers and program managers in promoting timely diagnosis and enhancing access to cancer treatment for all. By implementing effective strategies for early cancer detection, lives can be saved, and the personal, societal, and economic burdens of cancer care can be significantly reduced. As healthcare systems worldwide focus on early cancer detection and precision medicine, the demand for advanced diagnostic and monitoring tools, such as CTCs, has surged. CTCs play a critical role in cancer diagnostics by providing a non-invasive method to monitor tumor progression, metastasis, and response to treatment.

The rising prevalence of cancer globally is a significant driver of the CTC market. As cancer rates continue to climb, healthcare systems are increasingly prioritizing technologies that enable early detection, personalized treatment plans, and ongoing monitoring, all of which are made possible through the isolation and analysis of circulating tumor cells. In particular, CTCs offer valuable insights into the molecular characteristics of tumors, aiding in the development of targeted therapies.

Surge in Technological Advancements

The surge in technological advancements has emerged as a key driver of the global circulating tumor cells (CTC) market, significantly enhancing the detection, isolation, and analysis of these rare cells. The study of circulating tumor cells (CTCs) has led to significant breakthroughs, as they serve as key indicators of disseminating tumor subclones and liquid biopsy analytes. CTCs have enhanced our understanding of the metastatic process and have been integrated into the TNM staging system, allowing for the differentiation of metastatic breast cancer into stage IV indolent and stage IV aggressive disease based on CTC counts in the bloodstream. This inclusion highlights the prognostic importance of CTCs and their clinical value in risk assessment (tumor staging) and monitoring cancer treatment responses, particularly through minimal residual disease (MRD) detection. CTCs, which are cancer cells shed from primary tumors into the bloodstream, play a crucial role in cancer research and clinical oncology, offering valuable insights into tumor progression, metastasis, and treatment efficacy. Advances in technology have greatly improved the sensitivity and specificity of CTC detection methods, driving the expansion of the CTC market as these innovations enable more accurate diagnostics, personalized treatments, and improved patient outcomes.

One of the primary advancements fueling market growth is the development of highly sophisticated detection and isolation techniques. In recent years, the detection and analysis of circulating tumor DNA (ctDNA) have gained prominence in cancer research, particularly for the early diagnosis of hepatocellular carcinoma (HCC) and the monitoring of treatment effectiveness. Recent studies suggest that sequential ctDNA analysis in patients undergoing primary or adjuvant therapy for HCC can identify treatment resistance and recurrence before any visible morphological changes in the tumor, providing a valuable foundation for the timely adjustment of treatment strategies. New technologies, such as microfluidics-based platforms, immunomagnetic separation, and size-based filtration systems, have greatly improved the efficiency of isolating CTCs from the blood, overcoming challenges posed by their rarity and heterogeneity. These cutting-edge methods enable the detection of even minute concentrations of CTCs, providing earlier and more reliable diagnoses of metastatic cancer. As the demand for early cancer detection grows, these advanced technologies are driving the adoption of CTC-based diagnostics, expanding the market’s potential.

Download Free Sample Report

Key Market Challenges

High Costs of CTC-based Technologies

The process of isolating and detecting circulating tumor cells from a blood sample requires advanced technology due to the low concentration of CTCs in the bloodstream. Current methods, including microfluidics-based platforms, high-sensitivity imaging systems, and molecular analysis tools, are highly specialized and come with substantial costs. The complexity of these technologies often translates into expensive diagnostic tests, which can limit their accessibility for routine clinical use, especially in regions with constrained healthcare budgets.

Beyond the cost of the diagnostic tests themselves, the research and development (R&D) expenses involved in creating CTC-based technologies are significant. Companies and research institutions invest heavily in developing more efficient and sensitive tools for capturing and analyzing CTCs, but these innovations come at a high price. Additionally, maintaining the sophisticated equipment required for CTC detection, along with the necessary training for healthcare professionals to operate these systems, further increases operational costs for clinical laboratories.

Key Market Trends

Increasing Demand for Non-Invasive Diagnostics

The increasing demand for non-invasive diagnostics is emerging as a significant trend in the global circulating tumor cells (CTCs) market. As healthcare providers and patients alike seek safer, more convenient alternatives to traditional biopsy methods, non-invasive diagnostics, particularly those utilizing CTCs, are gaining widespread acceptance. This trend reflects a growing preference for techniques that can detect and monitor cancer without the need for invasive procedures.

CTCs provide a critical advantage in this context by enabling liquid biopsy, a non-invasive method of analyzing tumor cells through a simple blood draw. FDA-approved tests undergo extensive research to ensure their safety and accuracy. Numerous liquid biopsy tests are currently in development and various stages of research. One such example is the CellSearch Circulating Tumor Cell (CTC) Test, which detects CTCs and is used to predict outcomes for individuals with metastatic breast, prostate, or colon cancer. This test aids healthcare providers in monitoring patient conditions. A low count of CTCs in the blood indicates a favorable prognosis, while a high count suggests an unfavorable prognosis. Liquid biopsies are becoming increasingly popular for their ability to offer real-time insights into cancer progression, metastasis, and response to treatment, all while minimizing patient discomfort and reducing the risk of complications. This shift towards non-invasive diagnostics is transforming cancer care, allowing for more frequent monitoring and earlier detection of treatment resistance or disease recurrence.

Segmental Insights

Product Insights

Based on Product, Kits & Reagents have emerged as the fastest growing segment in the Global Circulating Tumor Cells Market in 2024. One key reason for this rapid growth is the increasing need for standardized and user-friendly solutions in CTC analysis. Kits and reagents, designed for specific detection platforms, offer pre-packaged and optimized materials that significantly reduce the complexity of the testing process. This standardization helps laboratories achieve consistent results across various samples, making the analysis process more reliable and reproducible. As more healthcare institutions and research facilities adopt CTC-based liquid biopsy techniques, the demand for high-quality kits and reagents has surged, driving their growth as a key segment in the market.

Technology Insights

Based on Technology, CTC Detection & Enrichment Methods have emerged as the fastest growing segment in the Global Circulating Tumor Cells Market during the forecast period. The rising incidence of cancer worldwide has led to a growing need for more precise and early-stage diagnostic tools. CTC detection and enrichment methods offer a non-invasive approach to identifying cancer cells in the bloodstream, allowing for earlier detection and monitoring of cancer progression. The demand for these technologies is rapidly increasing, as early detection significantly improves patient outcomes.

Download Free Sample Report

Regional Insights

Based on Region, North America have emerged as the dominating region in the Global Circulating Tumor Cells Market in 2024. The region boasts one of the most sophisticated healthcare infrastructures in the world, which facilitates the adoption of cutting-edge technologies such as CTC detection. Hospitals, research centers, and clinical laboratories in North America are equipped with the necessary resources and expertise to incorporate CTC-based diagnostics and monitoring systems into cancer care. This advanced infrastructure supports the widespread implementation of innovative, non-invasive diagnostic tools like liquid biopsy.

Recent Development

• In June 2024, Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics, announced the launch of Celselect Slides 2.0, designed to enhance the capture of rare cells and circulating tumor cells (CTCs). The upgraded Celselect Slides, compatible with Bio-Rad’s Genesis Cell Isolation System, allow for the processing of larger liquid biopsy sample volumes and significantly improve the capture and recovery of CTCs for enumeration or further downstream applications.
• In November 2024, RGCC, a leader in advanced diagnostic technologies, and the Indonesian Association of Surgical Oncology Experts (PERABOI) signed a Memorandum of Understanding (MOU) with PT Wapindo Jasaartha (Klinik Simas Sehat) to initiate a clinical study exploring the role of liquid biopsy (Circulating Tumor Cells) in monitoring treatment outcomes for breast cancer patients undergoing neoadjuvant chemotherapy. This observational, prospective cohort study will involve approximately 60 patients with stage II-III triple-negative breast cancer (TNBC) and HER2-enriched subtypes. Conducted across three hospitals in Indonesia, the study will utilize RGCC’s proprietary Oncotrace and Onconomics panels to assess CTC profiles at various stages of patient treatment.
• In March 2025, Sheba Medical Center and Tethis announced a research collaboration to evaluate circulating tumor cells (CTCs) in rectal cancer patients using Tethis' proprietary technology. As part of the initiative, Sheba Medical Center will deploy Tethis’ See.d instrument at its Institute of Pathology to investigate how AI-driven liquid biopsy can enhance treatment monitoring and enable early detection of cancer recurrence. By analyzing both circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in rectal cancer patients, the study seeks to establish baseline CTC levels, monitor changes during treatment, and assess their potential as early indicators of disease recurrence.
• In May 2024, Tempus, a leader in artificial intelligence and precision medicine, announced the clinical launch of its minimal residual disease (MRD) test portfolio, including the Tempus xM test and the xM (NeXT Personal Dx) test by Personalis. This portfolio offers both tumor-naïve and tumor-informed assays, designed to detect residual disease or early cancer recurrence and monitor immunotherapy treatment responses, providing critical insights to guide patient management strategies. The introduction of these assays further enhances Tempus' comprehensive testing offerings.

Key Market Players

• QIAGEN N.V.
• Bio-Techne Corp.
• Precision Medicine Group, LLC
• Bio-Rad Laboratories, Inc.
• Natera, Inc.
• Illumina, Inc.
• Greiner Bio-One International GmbH
• Ikonisys Inc.
• Creative Bioarray
• Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Circulating Tumor Cells Market, By Product:

o   Kits & Reagents

o   Blood Collection Tubes

o   Devices or Systems

• Circulating Tumor Cells Market, By Technology:

o   CTC Detection & Enrichment Methods

o   CTC Direct Detection Methods

o   CTC Analysis

• Circulating Tumor Cells Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Circulating Tumor Cells Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com